[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
April 1999

Long-term Use of Sedative and Hypnotic Medication

Arch Gen Psychiatry. 1999;56(4):355. doi:10.1001/archpsyc.56.4.355

THE ARTICLE by Bunney et al1 is a partial report of the efficacy and safety of triazolam (Halcion; Upjohn Co, Kalamazoo, Mich) for use as a sedative and hypnotic medication. The report was requested by the Food and Drug Administration (FDA) task force to provide an independent assessment of the safety and efficacy of this compound. The 7 recommendations of this report suggest the need for more data, better integration of clinical trial and postmarketing surveillance data, increased attention to long-term clinical trials, and development of methods to assess long-term effects, in terms of efficacy, tolerance, and safety.

First Page Preview View Large
First page PDF preview
First page PDF preview
×